New Strategies for Gene Therapy - A Bioscience Centre Conference
29th-30th September 1999, The Bioscience Centre, The International Centre
for Life, Newcastle upon Tyne, UK.
The full programme of speakers for this conference is now available. please
find details below.
28th September 1999, 6.00 pm - 7.15 pm welcome reception
29th September 1999, 9.30 am - 5.30 pm conference sessions
8.00 pm conference dinner
30th September 1999, 9.30 am - 3.00 pm conference sessions
All timings subject to confirmation.
Gene therapy is an innovative technique with the potential to control and
treat diseases based on the modification of an individuals genes. The main
obstacle for gene therapy is the ability to target a gene to specific cells
or tissues. The overall success of gene therapy as a therapeutic tool relies
on the right vector technology combined with the individual clinical needs
of the patient. This one-day conference will focus on strategies for
delivering genetic material to target cells by the use of viral and
non-viral vectors, focusing on specific diseases and cancers.
Novel Technologies for the Treatment of Cytokine and
Cytokine-receptor Related Diseases.
Novel technologies of pre-transcriptional regulation using promoter
inhibitors, and post-transcriptional regulation using ribozymes, have been
developed to inhibit cytokines and cytokine receptors involved in
pathogenesis of diseases.
Dr Richard Zheng, Queen Mary and Westfield College, University of London
Gene Therapy Unrequited Promise or Millennial Blockbuster?
Gene Therapy has now been around for 10 years. This talk will discuss
progress in gene therapy and the current prospects for gene therapy
Dr David Thatcher, Cobra Therapeutics
Development of the Adenovirus as a Gene Transfer Vector.
Its use in gene therapy and gene therapeutics and its application in
skeletal muscle as a model example.
Dr Michael Roberts, Royal Holloway and Bedford New College, University of
Oligonucleotide Strategies for Gene Correction:
Chimaeroplasts and Splicomers.
The use of oligonucleotides as an alternative to conventional gene therapy
approaches with an emphasis on the treatment of neuromuscular disease.
Dr Ian Graham, Royal Holloway and Bedford New College, University of London
Gene Therapy for Ischaemic Disease.
Transcriptional targeting and cell based gene therapy
utilising a range of vector systems for the treatment of
ischaemic diseases including solid tumours, arthritis,
peripheral arterial disease and cardiovascular disease.
Dr Stuart Naylor, Oxford Biomedica
Mitochondrial Gene Therapy.
Defects of mitochondrial DNA are an important cause of
disease currently with no effective treatment. Correcting
mitochondrial gene defects presents many different
challenges to nuclear gene therapy.
Professor Douglas Turnbull, Department of Neurology, University of Newcastle
New Approaches in Cancer Gene Therapy
Describing the integration of various recent cancer therapy strategies into
a co-ordinated therapeutic approach.
Dr Georges Vassaux, ICRF, Hammersmith Hospital
Development of a mutli-CTL epitope DNA prime-MVA boost vaccine for HIV.
Induction of CTL and their role(s) in the control of HIV infection.
Dr Tomas Hanke, MRC Human Immunology Unit, The John Radcliffe Hospital,
Progress Towards Third Generation Non-Viral Vectors for Gene Therapy
Liposomal gene therapy delivery
Dr Andrew Miller, Imperial College, University of London
Gene Therapy of Cystic Fibrosis using a liposome delivery system.
A review of the progress towards clinically effective gene therapy for
Dr Eric Alton, Imperial College, University of London
Full 2-day conference rate: £799.00 (+ £140.00 VAT) = £939.00
Full 1-day conference rate: £425.00 (+£74.38 VAT) = £499.38
Academic 2-day conference rate: £599.00 (+ £104.83 VAT) = £703.83
Academic 1-day conference rate: £325.00 (+ £56.88 VAT) = £381.88
These rates all include the conference dinner on the evening of 29th
For further information and to book contact the conference organisers:
Sue Reay or Claire Molloy
Tel: +44 191 421 0082 Fax: +44 191 438 1867
E-mail: Bioscience.conferences at benchcom.co.uk